- Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activityJoanne van Ryn
Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
Thromb Haemost 103:1116-27. 2010....
- Interpretation of point-of-care INR results in patients treated with dabigatranJoanne van Ryn
Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
Am J Med 125:417-20. 2012..However, case reports have identified falsely elevated point-of-care INR levels in patients treated with dabigatran using one of these devices (Hemochron). This in vitro study was designed to verify this issue...
- Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justificationAndreas Clemens
Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
Curr Med Res Opin 28:195-201. 2012..Based on its pharmacokinetic profile, dabigatran is dosed twice daily. This analysis provides a quantitative rationale for the selection of the dose regimen in this population...
- The discovery of dabigatran etexilateJoanne van Ryn
Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH and Co KG Biberach an der Riss, Baden Wurttemberg, Germany
Front Pharmacol 4:12. 2013....